Nipocalimab in Myasthenia Gravis: Real-World Use, Long-Term Safety, and the Road Ahead
NeurologyLive Published 17 Oct 2026 Relevancy: 29%
Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.
Discuss (0) Read the article